<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Efficacy and safety of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional DMARDs in patients with RA at week 97 (SUMMACTA)</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
				<date type="published" when="2015-06-08">8 June 2015</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author role="corresp">
							<persName><roleName>Dr</roleName><forename type="first">Gerd</forename><forename type="middle">R</forename><surname>Burmester</surname></persName>
							<email>gerd.burmester@charite.de</email>
							<affiliation key="aff1">
								<orgName type="institution">Free University and Humboldt University of Berlin</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Andrea</forename><surname>Rubbert-Roth</surname></persName>
							<affiliation key="aff2">
								<orgName type="institution">Universität zu Köln</orgName>
								<address>
									<settlement>Köln</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Alain</forename><surname>Cantagrel</surname></persName>
							<affiliation key="aff3">
								<orgName type="institution">Centre Hospitalier Universitaire de Toulouse</orgName>
								<address>
									<settlement>Toulouse</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Stephen</forename><surname>Hall</surname></persName>
							<affiliation key="aff4">
								<orgName type="institution">Cabrini Medical Centre</orgName>
								<address>
									<settlement>Malvern</settlement>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Piotr</forename><surname>Leszczynski</surname></persName>
							<affiliation key="aff5">
								<orgName type="institution">Poznan Medical University</orgName>
								<address>
									<settlement>Poznan</settlement>
									<country key="PL">Poland</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Daniel</forename><surname>Feldman</surname></persName>
							<affiliation key="aff6">
								<orgName type="institution">Universidade Federal de São Paulo</orgName>
								<address>
									<settlement>São Paulo</settlement>
									<country key="BR">Brazil</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Madura</forename><forename type="middle">J</forename><surname>Rangaraj</surname></persName>
							<affiliation key="aff7">
								<orgName type="institution">Arthritis &amp; Diabetes Clinic, Inc</orgName>
								<address>
									<settlement>Monroe</settlement>
									<region>Louisiana</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Georgia</forename><surname>Roane</surname></persName>
							<affiliation key="aff8">
								<orgName type="institution">Rheumatology Associates of South Carolina</orgName>
								<address>
									<settlement>Charleston</settlement>
									<region>South Carolina</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Charles</forename><surname>Ludivico</surname></persName>
							<affiliation key="aff9">
								<orgName type="institution">East Penn Rheumatology Associates</orgName>
								<address>
									<settlement>Bethlehem</settlement>
									<region>Pennsylvania</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Min</forename><surname>Bao</surname></persName>
							<affiliation key="aff10">
								<orgName type="institution">Genentech Inc</orgName>
								<address>
									<addrLine>South San Francisco</addrLine>
									<region>California</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Lucy</forename><surname>Rowell</surname></persName>
							<affiliation key="aff11">
								<orgName type="institution">Roche Products Limited</orgName>
								<address>
									<settlement>Welwyn Garden City</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Claire</forename><surname>Davies</surname></persName>
							<affiliation key="aff11">
								<orgName type="institution">Roche Products Limited</orgName>
								<address>
									<settlement>Welwyn Garden City</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Eduardo</forename><forename type="middle">F</forename><surname>Mysler</surname></persName>
							<affiliation key="aff12">
								<orgName type="institution">Organizacion Medica de Investigación</orgName>
								<address>
									<settlement>Buenos Aires</settlement>
									<country key="AR">Argentina</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff0">
								<orgName type="department">Department of Rheumatology and Clinical Immunology</orgName>
								<orgName type="institution">Charité-Universitätsmedizin Berlin</orgName>
								<address>
									<addrLine>Charitéplatz 1</addrLine>
									<postCode>10117</postCode>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Efficacy and safety of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional DMARDs in patients with RA at week 97 (SUMMACTA)</title>
					</analytic>
					<monogr>
						<imprint>
							<date type="published" when="2015-06-08">8 June 2015</date>
						</imprint>
					</monogr>
					<idno type="MD5">5EBCA94D135DBE85FE3A17E0F242A01D</idno>
					<idno type="DOI">10.1136/annrheumdis-2015-207281</idno>
					<note type="submission">Received 9 January 2015 Revised 23 April 2015 Accepted 10 May 2015</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:51+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Objectives To evaluate the long-term efficacy and safety of subcutaneous (SC) tocilizumab (TCZ) versus intravenous (IV) TCZ, including switching formulations, in patients with rheumatoid arthritis (RA) and inadequate response to disease-modifying antirheumatic drugs (DMARDs).</s><s>Methods Patients (n=1262) were randomised 1:1 to receive TCZ-SC 162 mg weekly (qw)+placebo-IV every four weeks (q4w) or TCZ-IV 8 mg/kg q4w+placebo-SC qw in combination with DMARD(s).</s><s>After a 24-week double-blind period, patients receiving TCZ-SC were rerandomised 11:1 to TCZ-SC (n=521) or TCZ-IV (TCZ-SC-IV, n=48), and patients receiving TCZ-IV were rerandomised 2:1 to TCZ-IV (n=372) or TCZ-SC (TCZ-IV-SC; n=186).</s><s>Maintenance of clinical responses and safety through week 97 were assessed.</s><s>Results The proportions of patients who achieved American College of Rheumatology (ACR)20/50/70 responses, Disease Activity Score in 28 joints remission and improvement from baseline in Health Assessment Questionnaire Disability Index ≥0.3 were sustained through week 97 and comparable across arms.</s><s>TCZ-SC had a comparable safety profile to TCZ-IV through week 97, except that injection site reactions (ISRs) were more common with TCZ-SC.</s><s>Safety profiles in patients who switched were similar to those in patients who received continuous TCZ-SC or TCZ-IV treatment.</s><s>The proportion of patients who developed anti-TCZ antibodies remained low across treatment arms.</s><s>No association between anti-TCZ antibody development and clinical response or adverse events was observed.</s><s>Conclusions The long-term efficacy and safety of TCZ-SC was maintained and comparable to that of TCZ-IV, except for ISRs.</s><s>Profiles in patients who switched formulations were comparable to those in patients who received TCZ-IV or TCZ-SC.</s><s>TCZ-SC provides additional treatment options for patients with RA.</s><s>Trial registration number NCT01194414.</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>INTRODUCTION</head><p><s>Rheumatoid arthritis (RA) is a chronic, progressive disease associated with inflammation and degeneration of the joints and surrounding tissue.</s><s>Treatments that have demonstrated efficacy with a favourable safety profile, such as antitumor necrosis factor inhibitors (aTNFs), an interleukin 6 (IL-6) receptor antagonist, a Janus kinase inhibitor and a T-cell co-stimulator are available. 1</s><s>However, when faced with multiple choices, patients have demonstrated a preference for subcutaneous (SC) over intravenous (IV) therapies. <ref type="bibr">2 3</ref></s><s>ocilizumab (TCZ) is a recombinant humanised monoclonal antibody directed against the human IL-6 receptor.</s><s>Intravenous TCZ (TCZ-IV) is approved in over 100 countries and has demonstrated efficacy with a well-established safety profile in patients with RA. <ref type="bibr" target="#b4">[4]</ref><ref type="bibr" target="#b5">[5]</ref><ref type="bibr" target="#b6">[6]</ref><ref type="bibr" target="#b7">[7]</ref><ref type="bibr" target="#b8">[8]</ref><ref type="bibr" target="#b9">[9]</ref> Subcutaneous TCZ (TCZ-SC) has demonstrated efficacy with a similar safety profile as TCZ-IV <ref type="bibr" target="#b10">[10]</ref><ref type="bibr" target="#b11">[11]</ref><ref type="bibr" target="#b12">[12]</ref><ref type="bibr" target="#b13">[13]</ref> and has been approved in the USA, Switzerland, Canada, Japan, and the European Union.</s></p><p><s>The phase III SUMMACTA study evaluated the efficacy and safety of TCZ-SC in combination with disease-modifying antirheumatic drugs (DMARDs) in patients with moderate-to-severe RA and inadequate response to ≥1 DMARD. <ref type="bibr" target="#b10">10</ref></s><s>SUMMACTA met its primary endpoint and demonstrated noninferiority of TCZ-SC 162 mg weekly (qw) to TCZ-IV 8 mg/kg every 4 weeks (q4w) with regard to the American College of Rheumatology 20 (ACR20) response at week 24.</s><s>TCZ-SC had a safety profile comparable to TCZ-IV. <ref type="bibr" target="#b10">10</ref> To assess the longterm efficacy and safety of TCZ-SC, data up to week 97 from the SUMMACTA study are evaluated here.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>PATIENTS AND METHODS Participants</head><p><s>Patient selection criteria were previously described. <ref type="bibr" target="#b10">10</ref></s><s>ll patients had an inadequate response to ≥1 DMARD, and ≤20% had an inadequate response to aTNF(s).</s><s>Patients continued to receive ≥1 nonbiological DMARD at the stable pre-entry dose.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Study design</head><p><s>SUMMACTA was a 97-week, randomised, doubledummy, active-controlled, parallel-group, multicentre phase III trial with a 24-week double-blind (DB) period followed by a 72-week open-label (OL) extension, with a 1-week dose interruption at week 24 before the first OL dosing at week 25 (figure <ref type="figure" target="#fig_0">1</ref>).</s><s>Patients were stratified by geographic region and body weight (&lt;60, 60 to &lt;100 or ≥100 kg).</s><s>At baseline, patients were randomised 1:1 to receive TCZ-SC 162 mg qw+placebo-IV q4w or TCZ-IV 8 mg/kg q4w +placebo-SC qw for the 24-week DB period.</s><s>At week 24, patients in the TCZ-SC arm were re-randomised 11:1 to either continue to receive TCZ-SC or switch to TCZ-IV (TCZ-SC-IV), whereas patients in the TCZ-IV arm were re-randomised 2:1 to receive either TCZ-IV or TCZ-SC (TCZ-IV-SC).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Outcomes and assessments</head><p><s>Efficacy was assessed in the DB period at weeks 2, 4 and every four weeks thereafter and in the OL period at weeks 37, 49, 73 and 97 and/or at early withdrawal.</s><s>Clinical assessments included ACR20/50/70; Disease Activity Score in 28 joints using erythrocyte sedimentation rate (DAS28-ESR) remission (DAS28 &lt;2.6) and DAS28-ESR low-disease activity (LDA; DAS28 &lt;3.2); Clinical Disease Activity Index (CDAI) remission (CDAI ≤2.8) and Boolean remission; withdrawal due to lack of therapeutic response; Health Assessment Questionnaire Disability Index (HAQ-DI) response (HAQ-DI score decreases of ≥0.3); and changes in HAQ-DI score.</s><s>TCZ serum concentration was monitored for pharmacokinetic (PK) analysis.</s><s>Pharmacodynamic (PD) parameters included C reactive protein (CRP) level and ESR.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Safety and immunogenicity</head><p><s>Safety was assessed throughout the study and for 8 weeks after week 97 or early withdrawal.</s><s>Assessments included adverse events (AEs) and laboratory parameters at weeks 2, 4 and every four weeks thereafter.</s><s>Anti-TCZ antibodies were assessed as previously described. <ref type="bibr" target="#b10">10</ref></s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Statistical methods</head><p><s>The intent-to-treat (ITT) population was used for all laboratory analyses and included patients who completed 24 weeks of DB treatment, were re-randomised at week 24 and received ≥1 TCZ dose after re-randomisation.</s><s>Efficacy analyses included patients who also had a valid assessment at the time point analysed (completer analysis).</s></p><p><s>The ITT-PK population included all patients eligible for the ITT population who provided ≥1 sample evaluable for PK analysis.</s><s>The safety population included all patients who received ≥1 dose of study drug and had ≥1 postdose safety assessment.</s><s>Subgroup analyses for DAS28 remission and safety were conducted in all body weight categories.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>RESULTS</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Patient disposition and baseline characteristics</head><p><s>A total of 1136 patients completed week 24 and 1135 entered the OL period (figure <ref type="figure" target="#fig_1">2</ref>).</s><s>The ITT population consisted of 521 patients in the TCZ-SC arm, 372 in the TCZ-IV arm, 186 in the TCZ-IV-SC arm and 48 in the TCZ-SC-IV arm.</s><s>During the OL period, safety-related withdrawals occurred in 37 patients (7.1%) in the TCZ-SC arm, 24 (6.5%) in the TCZ-IV arm, 14 (7.5%) in the TCZ-IV-SC arm and 2 (4.2%) in the TCZ-SC-IV arm.</s></p><p><s>Baseline demographics and clinical characteristics were balanced across arms (see online supplementary table <ref type="table" target="#tab_0">S1</ref>); exceptions were the proportions of patients positive for anticitrullinated protein antibody (ACPA) and rheumatoid factor, which were lower in the TCZ-SC-IV arm than the TCZ-SC arm and higher in the TCZ-IV-SC arm than the TCZ-IV arm.</s><s>Additionally, patients who received previous aTNFs were higher in the TCZ-SC-IV arm than the TCZ-SC arm and lower in the TCZ-IV-SC arm than the TCZ-IV arm.</s><s>In the TCZ-SC-IV arm, oral glucocorticoid use was lower and RA duration was longer compared with other arms.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Efficacy</head><p><s>The proportions of completer patients who achieved an ACR20 response at week 97 were 83.6% in the TCZ-SC arm and 83.3% in TCZ-IV arm compared with 75.5% and 78.2%, respectively, at week 24 (figure <ref type="figure" target="#fig_2">3A</ref>).</s><s>In the TCZ-IV-SC and TCZ-SC-IV arms, ACR20 responses were maintained after switching (weeks 24, 97: TCZ-IV-SC 79.6%, 88.5%; TCZ-SC-IV 68.8%, 82.5%; figure <ref type="figure" target="#fig_2">3B</ref>).</s><s>ACR50/70 responses were similar to ACR20 responses across all arms.</s><s>The ACR responses analysed in the ITT population showed similar results (see online supplementary figure <ref type="figure" target="#fig_0">S1</ref>).</s></p><p><s>The proportions of patients achieving DAS28 remission were similar in all groups at week 24 (≈37%) and were maintained to week 97 (TCZ-SC 53.4%, TCZ-IV 46.4%, TCZ-IV-SC 55.6%, TCZ-SC-IV 50.0%; figure <ref type="figure" target="#fig_2">3C</ref>).</s><s>Similar results were observed for DAS28 LDA (weeks 24, 97: TCZ-SC 54.5%, 67.0%; TCZ-IV 49.7%, 61.4%; TCZ-IV-SC 56.8%, 66.0%; TCZ-SC-IV 57.4%, 67.5%).</s><s>Following the 24-week randomised controlled trials, 25 (5.0%) and 24 (6.8%) patients at weeks 49 and 11 (2.5%) and 7 (2.3%) at week 97 in the TCZ-SC and TCZ-IV arms, respectively, achieved their first DAS28 remission status.</s></p><p><s>The proportions of patients who achieved HAQ-DI response at week 97 were comparable between the TCZ-SC and TCZ-IV arms (TCZ-SC 72.4%; TCZ-IV 69.1%) and were sustained after switching (TCZ-IV-SC 71.0%; TCZ-SC-IV 56.4%; figure <ref type="figure" target="#fig_2">3D</ref>).</s><s>The mean HAQ-DI score improved from ≈1.6 at baseline (see online supplementary table <ref type="table" target="#tab_0">S1</ref>) to ≈1.0 in all arms at week 24 and was maintained or decreased through week 97.</s></p><p><s>The proportions of patients achieving CDAI remission were maintained from week 24 through week 97 in the TCZ-SC and TCZ-IV arms (weeks 24, 97: TCZ-SC 13.5%, 27.2%; TCZ-IV 15.0%, 24.1%).</s><s>Rates were similar at week 97 in patients who switched (TCZ-IV-SC 27.3%, TCZ-SC-IV 30.0%).</s><s>Similar observations were noted for Boolean remission (see online supplementary figure <ref type="figure" target="#fig_1">S2</ref>).</s></p><p><s>In all body weight categories, the proportions of patients who achieved DAS28 remission were maintained from week 24 through week 97 (see online supplementary figure <ref type="figure" target="#fig_2">S3</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Pharmacokinetics and pharmacodynamics</head><p><s>The mean TCZ concentrations in patients receiving TCZ-SC were approximately twice those in patients receiving TCZ-IV through week 97, consistent with observations through week 24.</s><s>In patients who switched, concentrations were comparable to those in patients who received TCZ-SC or TCZ-IV continuously.</s><s>In both switch arms, steady-state TCZ concentrations from week 25 onwards were not affected by the original dosing regimens (figure <ref type="figure">4</ref>).</s></p><p><s>Mean CRP concentrations decreased to below the upper limit of normal (ULN; 0.99 mg/dL) after the first dose of TCZ and remained within normal range through week 97 in all arms (see online supplementary figure <ref type="figure">S4</ref>).</s><s>Mean ESR decreased during the first eight weeks in both TCZ-IV and TCZ-SC arms and remained low to week 97 in all arms (see online supplementary figure <ref type="figure">S5</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Safety</head><p><s>The safety profile of TCZ-SC remained stable over time.</s><s>At week 97, AEs and serious AE (SAE) rates were comparable in the TCZ-SC and TCZ-IV arms, with the exception of injection site reactions (ISRs), which occurred more frequently in patients receiving TCZ-SC than in patients receiving TCZ-IV; however, the overall frequency of ISRs decreased over 97 weeks.</s><s>All ISRs were Common Terminology Criteria for Adverse Events grade 1 or 2. The most common ISR symptom was erythema.</s></p><p><s>The safety profiles in patients who switched were similar to those continuing TCZ-SC or TCZ-IV (table 1 and see online supplementary table <ref type="table">S2</ref>).</s><s>Patient-year (PY)-adjusted AE rates in the TCZ-IV-SC arm were comparable to those in the TCZ-IV arm.</s><s>Some AE rates were higher in the TCZ-IV-SC arm, but 95% CIs were wide and overlapped with the TCZ-IV arm; exceptions were hypersensitivity rates, which were lower, and ISR rate, which was higher than the TCZ-IV arm.</s><s>The higher ISR rate after switching from TCZ-IV to TCZ-SC can be explained by multiple ISR episodes in five patients who reported ≥1 ISR symptom after almost every SC injection.</s><s>The ISR events were generally non-serious (grade 1).</s><s>Only one patient (TCZ-IV-SC arm) withdrew due to an ISR (erythema).</s><s>None of the ISR symptoms in the TCZ-IV-SC arm were reported as SAEs.</s><s>Although PYs in the TCZ-SC-IV arm were low (66.2</s><s>PY), PY-adjusted AE rates were overall comparable with those in the TCZ-SC arm.</s><s>Infection rates decreased over time in all arms.</s><s>Infections were the most commonly reported AEs (TCZ-SC 63.2%, TCZ-IV 57.8%, TCZ-IV-SC 17.7%, TCZ-SC-IV 56.3%) and led to withdrawal in 17 patients (2.7%) in the TCZ-SC arm, 12 (1.9%) in the TCZ-IV arm, 8 (4.3%) in the TCZ-IV-SC arm and 0 in the TCZ-SC-IV arm.</s></p><p><s>SAE rates were generally stable, consistent over 97 weeks, and comparable between the TCZ-SC and TCZ-IV arms.</s><s>Serious infection rates were maintained over time.</s><s>The rate of serious infections per 100 PY in the TCZ-IV-SC arm was higher (6.65 (95% CI 3.87 to 10.64)) than in the TCZ-IV arm (3.92 (95% CI 2.68 to 5.53)); however, the 95% CIs overlapped.</s><s>The most common serious infections occurring in ≥2 patients in the TCZ-SC, TCZ-IV and TCZ-IV-SC arms were cellulitis and pneumonia.</s><s>Only one serious infection (diverticulitis) was reported in the TCZ-SC-IV arm.</s><s>Opportunistic infection rates were consistent over time and were atypical pneumonia (patient withdrawn), bronchopulmonary aspergillosis, oropharyngeal candidiasis and pharyngeal abscess in the TCZ-SC arm; genital herpes zoster and lepromatous leprosy ( patient withdrawn) in the TCZ-IV arm; and genital herpes zoster, oropharyngeal candidiasis and Burkholderia pseudomallei infection (occurred in a major endemic region, Thailand) in the TCZ-IV-SC arm.</s><s>Ten deaths were reported: four in the TCZ-SC arm (shock, cerebral infarction, thrombosis and unknown cause), four in the TCZ-IV arm (acute respiratory distress, cerebral infarction, sepsis and idiopathic pulmonary fibrosis) and two in the TCZ-IV-SC arm (pneumonia and sepsis).</s></p><p><s>No anaphylaxis cases were identified (according to Sampson criteria).</s><s>Seven SAEs (five in the TCZ-SC arm and two in the TCZ-IV arm) were observed within 24 h of infusion/injection and evaluated as related to study treatment; of these, three were medically consistent with hypersensitivity and led to study withdrawal (two in the TCZ-SC arm and one in the TCZ-IV arm).</s><s>One patient in the TCZ-SC arm and two in the TCZ-IV-SC arm experienced medically confirmed gastrointestinal perforations.</s></p><p><s>A similar frequency of elevated liver enzymes was observed in all treatment arms; there were no Hy's law cases.</s><s>Most shifts in aminotransferase levels were from normal at baseline to ≤3× the ULN and occurred at a single time point only.</s><s>The number of patients who experienced an alanine aminotransferase elevation ≥3× ULN in ≥2 consecutive samples over time was low.</s><s>One patient experienced consecutive aspartate aminotransferase elevations ≥3× ULN (see online supplementary table <ref type="table">S3</ref>).</s><s>Most 3) from baseline over 97 weeks (intent-to-treat population).</s><s>The ns refer to completer analysis.</s><s>For TCZ-SC and TCZ-IV, this refers to patients who continued on TCZ-SC or TCZ-IV from baseline through the open-label period; patients who switched are not included in this population.</s><s>If a patient withdrew prior to week 97 but had efficacy measurements between weeks 85 and 96, the patient was still counted for efficacy analysis but not as a patient who completed week 97.</s><s>qw, weekly; q4w, every four weeks.</s><s>cases of neutropenia were newly occurring.</s><s>The majority of events occurred at one or two consecutive visits (see online sup-plementary table <ref type="table">S3</ref>).</s><s>Also, 10 patients (1.9%) in the TCZ-SC arm, 10 (2.7%) in the TCZ-IV arm, 2 (1.1%) in the TCZ-IV-SC arm and 0 in the TCZ-SC-IV arm experienced grade 3 or 4 neutropenia on ≥2 consecutive visits.</s><s>One patient (0.5%) in the TCZ-IV-SC arm had a serious infection of laryngitis (grade 3) that corresponded with grade 4 neutropenia.</s><s>Neutropenia AEs leading to withdrawal remained low over time: four patients in the TCZ-SC arm and three in the TCZ-IV withdrew at week 97 versus one patient in each arm at week 24.</s><s>No withdrawals due to neutropenia AEs occurred in either switch arm.</s><s>Most patients maintained a platelet count above the lower limit of normal throughout treatment.</s><s>One patient in the TCZ-IV arm experi-enced grade 3 thrombocytopenia (no grade 4; see online supple-mentary table <ref type="table">S3</ref>).</s><s>There was no association between grade 3 or 4 thrombocytopenia and serious bleeding events.</s><s>The propor-tion of patients reporting shifts in total cholesterol, low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol and triglycerides after initiation of TCZ was higher in the TCZ-SC arm than the TCZ-IV arm (total cholesterol 26.1% vs 21.0%; LDL 27.7% vs 23.2%; HDL 3.2% vs 3.9%; and triglycerides 23.8% vs 17.5%) at week 97, consistent with observations made at week 24 (see online supplementary table <ref type="table">S3</ref>).</s><s>With the exception of the TCZ-SC-IV arm, patients weighing ≥100 kg at baseline had higher rates of AEs/100 PYs compared with patients in the lighter subgroups (see online supplementary table <ref type="table">S4</ref>).</s><s>The incidence of SAEs was comparable in the TCZ-SC and TCZ-IV arms across the lower body weight sub-groups and higher in the TCZ-SC arm compared with the TCZ-IV arm in the ≥100 kg subgroup.</s><s>The overall SAE rate in the TCZ-IV-SC arm was higher than in the TCZ-IV arm in each of the weight subgroups, whereas in the TCZ-SC-IV arm, it was lower than in the TCZ-SC arm.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Immunogenicity</head><p><s>The proportions of patients who developed anti-TCZ antibodies postbaseline were low: 10 patients (1.6%) in the TCZ-SC arm, Figure <ref type="figure">4</ref> Mean (±SD) tocilizumab (TCZ) serum concentration over time (ITT-PK population) in patients treated with either subcutaneous TCZ (TCZ-SC; n=521) or intravenous TCZ (TCZ-IV; n=372) as well as patients who switched from TCZ-SC to TCZ-IV (TCZ-SC-IV; n=48) and vice versa (TCZ-IV-SC; n=186).</s><s>ITT, intent-to-treat; PK, pharmacokinetic; qw, weekly; q4w, every four weeks.</s><s>0.39 (0.11 to 1.01) [4]  0 (0 to 1.28) [0] 0.24 (0.03 to 0.88) [2]  1.17 *Data are included from the DB and OL periods for all treatment arms; therefore, safety analyses for the TCZ-IV and TCZ-SC arms include all data from patients who received TCZ-IV and TCZ-SC, respectively, up to week 24 (n=631 for each arm) as well as those who remained on TCZ-IV and TCZ-SC during the OL period.</s><s>†Excludes tuberculosis.</s><s>Up to the week 97 data cut-off, there was one case of latent tuberculosis in the TCZ-SC arm and zero in the other arms.</s><s>In the TCZ-SC arm, there was one case each of serious atypical pneumonia, serious bronchopulmonary aspergillosis, non-serious oropharyngeal candidiasis and serious pharyngeal abscess.</s><s>In the TCZ-IV arm, events included one case each of non-serious genital herpes zoster and non-serious lepromatous leprosy.</s><s>The events in the TCZ-IV-SC arm were one case each of non-serious genital herpes zoster, non-serious oropharyngeal candidiasis and serious Burkholderia pseudomallei infection (the case occurred in Thailand, recognised as a major endemic region for B. pseudomallei).</s></p><p><s>‡Serious AEs occurring during or within 24 h of the injection/infusion, excluding injection site reactions, and not deemed to be unrelated to treatment by the investigator.</s><s>§All malignant and unspecified tumours, including non-melanoma skin cancer adverse events, were included.</s><s>¶Medically confirmed.</s><s>**Patients died of shock (Spain), cerebral infarction ×2 (Bulgaria and Russia), thrombosis (the USA), unknown cause (the USA), acute respiratory distress (Canada), sepsis ×2 (Lithuania and the USA), idiopathic pulmonary fibrosis (the USA) and pneumonia (Canada).</s><s>AE, adverse event; DB, double-blind; GI, gastrointestinal; IV, intravenous; OL, open-label; PY, patient-year; qw, weekly; q4w, every four weeks; SAE, serious adverse event; SC, subcutaneous; TCZ, tocilizumab.</s></p><p><s>7 (1.1%) in the TCZ-IV arm, 0 in the TCZ-SC-IV arm and 1 (0.5%) in the TCZ-IV-SC arm.</s><s>No correlation between anti-TCZ antibody development and clinical response or AEs was observed.</s><s>Among patients who developed anti-TCZ antibodies, two in the TCZ-IV arm experienced ISRs.</s><s>No patients with serious hypersensitivity events or who withdrew due to efficacy reasons developed anti-TCZ antibodies.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>DISCUSSION</head><p><s>Efficacy, safety and PK/PD profiles were maintained with continuous TCZ dosing through week 97.</s><s>Efficacy in the TCZ-SC and TCZ-IV arms was comparable from weeks 24 to 97 for ACR20/50/70 response, DAS28 remission and HAQ-DI response rates.</s><s>The efficacy and safety profile in patients who switched formulations was comparable to that in patients who remained on TCZ-IV or TCZ-SC.</s><s>Lower ACR20/50/70 and HAQ-DI response rates occurred in the TCZ-SC-IV arm compared with the TCZ-SC arm; however, these lower values were observed from baseline through week 97.</s><s>Differences may be due to the lower number of patients in the TCZ-SC-IV arm or to baseline differentiating factors in this group, such as shorter RA duration, higher number of failed aTNFs, lower rates of ACPA positivity and oral corticosteroid use.</s><s>No new safety signals were identified, and the safety of TCZ-SC observed at week 24 was maintained with longer PYs.</s><s>TCZ-SC had a safety profile similar to the known safety profile of TCZ-IV, with the exception of ISRs, which were more common with TCZ-SC.</s></p><p><s>In patients who switched formulations, the safety profile was comparable to patients who received the same formulation throughout the study.</s><s>AE rates in the TCZ-SC-IV arm were comparable to those in patients who continued to receive TCZ-SC.</s><s>In the TCZ-IV-SC arm, PY-adjusted AE rates during the OL period were generally comparable to those in the TCZ-IV arm and lower than in the TCZ-SC arm.</s><s>SAE rates (including serious infections) were consistent over time up to 2 years.</s><s>Serious infection rates were higher in the TCZ-IV-SC arm compared with the TCZ-IV arm.</s><s>However, for both arms, SAE rates, including serious and opportunistic infections, had overlapping CIs, indicating no significant differences.</s><s>Investigation into possible differences suggested that no baseline characteristics for age, weight, origin, prior aTNF treatment failure, baseline corticosteroid use or comorbidities appeared to favour the TCZ-IV arm.</s><s>Comorbidities, such as diabetes, chronic obstructive pulmonary disease (COPD) and tobacco use, which predispose patients to infections, were comparable in the TCZ-IV-SC arm and the TCZ-IV arm.</s><s>While there was a higher incidence of concurrent COPD in the TCZ-IV-SC arm (2.7%) compared with the TCZ-IV arm (1.8%), fewer patients in the TCZ-IV-SC arm (5.9%) had concurrent diabetes compared with the TCZ-IV (9.4%) and TCZ-SC arms (7.8%).</s></p><p><s>Immunogenicity of biological therapy has been a concern for healthcare providers.</s><s>However, the proportions of patients who developed anti-TCZ antibodies remained low and were comparable up to week 97 in all treatment arms, including the switch arms.</s><s>No correlation of anti-TCZ antibody development with clinical response or AEs was observed.</s></p><p><s>In all treatment groups and body weight categories, DAS28 response rates were maintained with dose continuation and after switching formulations.</s><s>The data in the highest and lowest weight categories for the TCZ-SC-IV arm should be interpreted with caution due to the low number of patients in these groups.</s><s>Infection risk factors, such as diabetes and COPD, could explain the numerically higher incidences of AEs in the TCZ-SC and TCZ-IV arms among patients weighing ≥100 kg at baseline compared with patients weighing &lt;100 kg.</s><s>A higher proportion of patients in the ≥100 kg category had diabetes or COPD (diabetes: TCZ-SC 22.6%, TCZ-IV 17.5%; COPD: TCZ-SC 4.8%, TCZ-IV 3.2%) compared with the 60 to 100 kg category (diabetes: TCZ-SC 6.6%, TCZ-IV 8.5%; COPD: TCZ-SC 2.8%, TCZ-IV 1.7%) and the &lt;60 kg category (diabetes: TCZ-SC 4.9%, TCZ-IV 2.1%; COPD: TCZ-SC 0%, TCZ-IV 2.7%).</s></p><p><s>The long-term efficacy and safety of TCZ-SC was maintained and remained comparable with that of TCZ-IV, with the exception of ISRs.</s><s>Efficacy in patients who switched between formulations was maintained, and safety profiles were similar to those in patients who remained on TCZ-IV or TCZ-SC.</s><s>Most AE rates were comparable, with wide and overlapping 95% CIs.</s><s>TCZ-SC could provide a more convenient administration option for patients with RA.</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>Figure 1</head><label>1</label><figDesc><div><p><s>Figure 1 Study design.</s><s>All patients continued to receive ≥1 permitted traditional disease-modifying antirheumatic drug at the stable pre-entry dose as prescribed by the treating physician.</s><s>DB, double-blind; DI, dose interruption; IV, intravenous; OL, open-label; qw, weekly; q4w, every four weeks; R, randomisation; SC, subcutaneous; TCZ, tocilizumab.</s></p></div></figDesc><graphic coords="2,117.64,48.42,360.00,122.12" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>Figure 2</head><label>2</label><figDesc><div><p><s>Figure 2 Patient disposition over 97 weeks.</s><s>All patients received ≥1 dose of study drug and were eligible for inclusion in the intent-to-treat (all patients who received ≥1 dose of study drug) and safety (all patients who received ≥1 dose of TCZ and had ≥1 postdose safety assessment) populations.</s><s>AE, adverse event; IV, intravenous; OL, open-label; qw, weekly; q4w, every 4 weeks; SC, subcutaneous; TCZ, tocilizumab.</s></p></div></figDesc><graphic coords="3,60.66,48.42,473.95,354.44" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head>Figure 3</head><label>3</label><figDesc><div><p><s>Figure 3 Proportion of patients treated with either (A) subcutaneous tocilizumab (TCZ-SC; n=521) or intravenous tocilizumab (TCZ-IV; n=372) as well as (B) patients who switched from TCZ-SC to TCZ-IV (TCZ-SC-IV; n=48) and vice versa (TCZ-IV-SC; n=186) achieving 20%, 50% and 70% improvements per the American College of Rheumatology criteria (ACR20, ACR50 and ACR70), (C) remission based on Disease Activity Score using 28 joints (DAS28 &lt;2.6) and (D) Health Assessment Questionnaire-Disease Index (HAQ-DI) response (HAQ-DI score decreases of ≥0.3) from baseline over 97 weeks (intent-to-treat population).</s><s>The ns refer to completer analysis.</s><s>For TCZ-SC and TCZ-IV, this refers to patients who continued on TCZ-SC or TCZ-IV from baseline through the open-label period; patients who switched are not included in this population.</s><s>If a patient withdrew prior to week 97 but had efficacy measurements between weeks 85 and 96, the patient was still counted for efficacy analysis but not as a patient who completed week 97.</s><s>qw, weekly; q4w, every four weeks.</s></p></div></figDesc><graphic coords="4,81.64,48.42,432.00,356.49" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_3"><head></head><label></label><figDesc><div><p><s>(0.24 to 3.43)[3]  0.00 (0 to 5.57) [0] Serious hypersensitivity events ‡ 0.69 (0.08 to 2.49)[2]  0.49 (0.16 to 1.15)[5]  1.04 (0.21 to 3.04)[3]  0.24 (0.03 to 0.88)</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>Table 1</head><label>1</label><figDesc><div><p><s>Overview of cumulative AEs and serious AEs (SAEs) at week 97 (safety population*)</s></p></div></figDesc><table><row><cell></cell><cell>TCZ-SC 162 mg qw (n=631)</cell><cell></cell><cell>TCZ-IV 8 mg/kg q4w (n=631)</cell><cell></cell><cell>TCZ-IV-SC (n=186)</cell><cell>TCZ-SC-IV (n=48)</cell></row><row><cell>Rate/100 PY (95% CI) [no. of events]</cell><cell>24 weeks</cell><cell>97 weeks</cell><cell>24 weeks</cell><cell>97 weeks</cell><cell>97 weeks</cell><cell>97 weeks</cell></row><row><cell>No. of PYs of exposure</cell><cell>289.82</cell><cell>1013.26</cell><cell>288.39</cell><cell>816.53</cell><cell>255.75</cell><cell>66.19</cell></row></table><note><p><s>SAEs  11.73(8.12to</s><s>16.39) [34] 14.61 (12.35 to 17.16) [148] 14.91 (10.79 to 20.08) [43] 15.43 (12.85 to 18.37) [126] 19.55 (14.51 to 25.78) [50] 9.06 (3.33 to 19.73) [6] Serious infections 3.11 (1.42 to 5.89) [9] 3.95 (2.82 to 5.38) [40] 3.47 (1.66 to 6.38) [10] 3.92 (2.68 to 5.53) [32] 6.65 (3.87 to 10.64) [17] 1.51 (0.04 to 8.42) [1] Opportunistic infections † 0.35 (0.01 to 1.92) [1]</s></p></note></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">on May 17, 2022 by guest. Protected by copyright. http://ard.bmj.com/ Ann Rheum Dis: first published as 10.1136/annrheumdis-2015-207281 on 8 June 2015. Downloaded from</note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" n="1">Agarwal SK. Biologic agents in rheumatoid arthritis: an update for managed care professionals. J Manag Care Pharm 2011;17:S14-18.</note>
		</body>
		<back>

			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Acknowledgements The authors wish to thank all investigators and patients who participated in the study and all members of the WA22762 study team.</s></p><p><s>Contributors MB and LR designed the study, analysed and interpreted the data.</s><s>CD and GRB analysed and interpreted the data.</s><s>GRB, AR-R, AC, SH, PL, DF, MJR, GR, CL, and EFM were involved in generating the data at their clinical research sites.</s><s>All authors were involved in writing the manuscript and approved it.</s></p><p><s>Funding Support for third-party writing assistance for this manuscript, furnished by Denise Kenski, PhD, and Ramona Pufan, PhD, of Health Interactions, was provided by F. Hoffmann-La Roche, Ltd.</s><s>Roche sponsored the study and participated in the design of the study, as well as in the collection, analysis and interpretation of the data.</s><s>This manuscript was reviewed by Roche, but the decision to submit and publish this manuscript was contingent only upon the approval of the lead author and co-authors, including those employed by Roche.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Competing interests</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Ethics approval</head><p><s>The study was conducted in accordance with the Declaration of Helsinki and good clinical practice.</s></p></div>
			</div>

			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<monogr>
		<title/>
		<idno type="DOI">10.1136/annrheumdis-2015-207281on8</idno>
		<ptr target="http://ard.bmj.com/" />
		<imprint>
			<date type="published" when="2015-06">June 2015. May 17</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">Ann</forename><surname>Rheum</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Dis</forename></persName>
		</author>
		<idno type="DOI">10.1136/annrheumdis-2015-207281on8</idno>
		<imprint>
			<date type="published" when="2015-06">June 2015</date>
		</imprint>
	</monogr>
	<note>Downloaded from</note>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Preferences of patients and health professionals for route and frequency of administration of biologic agents in the treatment of rheumatoid arthritis</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">K</forename><surname>Huynh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Ostergaard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Egsmose</surname></persName>
		</author>
		<idno type="DOI">10.2147/PPA.S55156</idno>
	</analytic>
	<monogr>
		<title level="j">Patient Prefer Adherence</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page" from="93" to="99" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Patient preferences and satisfaction in the treatment of rheumatoid arthritis with biologic therapy</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Barton</surname></persName>
		</author>
		<idno type="DOI">10.2147/PPA.S5835</idno>
	</analytic>
	<monogr>
		<title level="j">Patient Prefer Adherence</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="page" from="335" to="344" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">S</forename><surname>Smolen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Beaulieu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Rubbert-Roth</surname></persName>
		</author>
		<idno type="DOI">10.1016/S0140-6736(08)60453-5</idno>
	</analytic>
	<monogr>
		<title level="j">Lancet</title>
		<imprint>
			<biblScope unit="volume">371</biblScope>
			<biblScope unit="page" from="987" to="997" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Genovese</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">D</forename><surname>Mckay</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">L</forename><surname>Nasonov</surname></persName>
		</author>
		<idno type="DOI">10.1002/art.23940</idno>
	</analytic>
	<monogr>
		<title level="j">Arthritis Rheum</title>
		<imprint>
			<biblScope unit="volume">58</biblScope>
			<biblScope unit="page" from="2968" to="2980" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial</title>
		<author>
			<persName><forename type="first">P</forename><surname>Emery</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Keystone</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">P</forename><surname>Tony</surname></persName>
		</author>
		<idno type="DOI">10.1136/ard.2008.092932</idno>
	</analytic>
	<monogr>
		<title level="j">Ann Rheum Dis</title>
		<imprint>
			<biblScope unit="volume">67</biblScope>
			<biblScope unit="page" from="1516" to="1523" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study</title>
		<author>
			<persName><forename type="first">G</forename><surname>Jones</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Sebba</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Gu</surname></persName>
		</author>
		<idno type="DOI">10.1136/ard.2008.105197</idno>
	</analytic>
	<monogr>
		<title level="j">Ann Rheum Dis</title>
		<imprint>
			<biblScope unit="volume">69</biblScope>
			<biblScope unit="page" from="88" to="96" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Kremer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Blanco</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Brzosko</surname></persName>
		</author>
		<idno type="DOI">10.1002/art.30158</idno>
	</analytic>
	<monogr>
		<title level="j">Arthritis Rheum</title>
		<imprint>
			<biblScope unit="volume">63</biblScope>
			<biblScope unit="page" from="609" to="621" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial</title>
		<author>
			<persName><forename type="first">C</forename><surname>Gabay</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Emery</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Van Vollenhoven</surname></persName>
		</author>
		<idno type="DOI">10.1016/S0140-6736(13)60250-0</idno>
	</analytic>
	<monogr>
		<title level="j">Lancet</title>
		<imprint>
			<biblScope unit="volume">381</biblScope>
			<biblScope unit="page" from="1541" to="1550" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">A randomised, double-blind, parallel-group study of the safety and efficacy of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with moderate to severe rheumatoid arthritis (SUMMACTA study)</title>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">R</forename><surname>Burmester</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Rubbert-Roth</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Cantagrel</surname></persName>
		</author>
		<idno type="DOI">10.1136/annrheumdis-2013-203523</idno>
	</analytic>
	<monogr>
		<title level="j">Ann Rheum Dis</title>
		<imprint>
			<biblScope unit="volume">73</biblScope>
			<biblScope unit="page" from="69" to="74" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Subcutaneous tocilizumab versus placebo in combination with disease-modifying antirheumatic drugs in patients with rheumatoid arthritis</title>
		<author>
			<persName><forename type="first">A</forename><surname>Kivitz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Olech</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Borofsky</surname></persName>
		</author>
		<idno type="DOI">10.1002/acr.22384</idno>
	</analytic>
	<monogr>
		<title level="j">Arthritis Care Res (Hoboken)</title>
		<imprint>
			<biblScope unit="volume">66</biblScope>
			<biblScope unit="page" from="1653" to="1661" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Phase III study of the efficacy and safety of subcutaneous versus intravenous tocilizumab monotherapy in patients with rheumatoid arthritis</title>
		<author>
			<persName><forename type="first">A</forename><surname>Ogata</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Tanimura</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Sugimoto</surname></persName>
		</author>
		<idno type="DOI">10.1002/acr.22110</idno>
	</analytic>
	<monogr>
		<title level="j">Arthritis Care Res (Hoboken)</title>
		<imprint>
			<biblScope unit="volume">66</biblScope>
			<biblScope unit="page" from="344" to="354" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Potential patient benefit of a subcutaneous formulation of tocilizumab for the treatment of rheumatoid arthritis: a critical review</title>
		<author>
			<persName><forename type="first">E</forename><surname>Besada</surname></persName>
		</author>
		<idno type="DOI">10.2147/PPA.S34958</idno>
	</analytic>
	<monogr>
		<title level="j">Patient Prefer Adherence</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page" from="1051" to="1059" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title/>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">R</forename><surname>Burmester</surname></persName>
		</author>
		<idno type="DOI">10.1136/annrheumdis-2015-207281</idno>
	</analytic>
	<monogr>
		<title level="j">Ann Rheum Dis</title>
		<imprint>
			<biblScope unit="volume">75</biblScope>
			<biblScope unit="page" from="68" to="74" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<monogr>
		<title/>
		<author>
			<persName><surname>Clinical</surname></persName>
		</author>
		<author>
			<persName><surname>Research On</surname></persName>
		</author>
		<ptr target="http://ard.bmj.com/" />
		<imprint>
			<date>May</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">Ann</forename><surname>Rheum</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Dis</forename></persName>
		</author>
		<idno type="DOI">10.1136/annrheumdis-2015-207281on8</idno>
		<imprint>
			<date type="published" when="2015-06">June 2015</date>
		</imprint>
	</monogr>
	<note>Downloaded from</note>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
